sabizabulin
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
6
Phase 3
2
Phase 4
0
Earliest trial started Jan 18, 2019 (NCT03752099)
Timeline
Indications
Mechanism of action
- TubulinINHIBITOR
Tubulin inhibitor
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin alpha-3C chain (TUBA3C) ↗
- Tubulin alpha-4A chain (TUBA4A) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin alpha-1A chain (TUBA1A) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin alpha-1B chain (TUBA1B) ↗
- Tubulin alpha-1C chain (TUBA1C) ↗
- Tubulin alpha-3E chain (TUBA3E) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc(C(=O)c2cnc(-c3c[nH]c4ccccc34)[nH]2)cc(OC)c1OC- Mol. weight
- 377.4 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2163631 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05008510 | Phase 2 | Dec 30, 2021 | Veru Inc. |
| NCT05079360 | Phase 2 | Nov 30, 2021 | Veru Inc. |
| NCT04844749 | Phase 3 | Jun 24, 2021 | Veru Inc. |
| NCT04842747 | Phase 3 | May 18, 2021 | Veru Inc. |
| NCT04388826 | Phase 2 | May 25, 2020 | Veru Inc. |
| NCT03752099 | Phase 1/Phase 2 (Phase 2) | Jan 18, 2019 | Veru Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Veru Inc. | For profit | 6 | 6 | 2 | 2019 |
1 organizations
Page 1 / 1